Clinical Trial: Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title:
Brief Summary: To determine the efficacy of intravitreal ranibizumab injection as adjuvant therapy in the treatment of postvitrectomy diabetic vitreous hemorrhage (PDVH) accompanied by neovascular glaucoma (NVG) as a means of preventing recurrent vitreous hemorrhage （VH） and optimizing postoperative intraocular pressure（IOP）control.
Detailed Summary:
Sponsor: Ruijin Hospital
Current Primary Outcome:
- vitreous hemorrhage [ Time Frame: 12 months ]
- intraocular pressure [ Time Frame: 12 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Ruijin Hospital
Dates:
Date Received: December 30, 2015
Date Started: January 2013
Date Completion:
Last Updated: January 4, 2016
Last Verified: January 2013
